Incidence and costs of polypharmacy: Data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2815-2822

  Rupnow, Marcia F T ^a   Greenspan, Andrew ^b   Gharabawi, Georges M ^a   Kosik Gonzalez, Colette ^a   Zhu, Young ^a   Stahl, Stephen M ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Polypharmacy; Quetiapine; Risperidone; Schizoaffective disorder; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; CHLORPROMAZINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LITHIUM; LOXAPINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TRAZODONE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEALTH CARE COST; HUMAN; INDIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; ROMANIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR; UNITED STATES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; POLYPHARMACY; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 36348974570     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233359     Document Type: Article

References (15)

1. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotic. BMC Psychiatry 2005;5:26
2. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88
3. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-27
4. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-6
5. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002;28:105-9
6. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84
7. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006;57:127-9
8. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15
9. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002;159:1932-5
10. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6
11. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine, and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-65
12. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
13. Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington (DC): US Department of Health, Education, and Welfare; 1976. p. 218-22 [Publication ADM 76-338]
14. IMS Health, National Disease and Therapeutic Index (NDTI), Schizophrenia Population, MAT December 2002 and December 2003
15. Rupnow M, Markowitz J. Psychotropic polypharmacy in Medicaid subjects with schizophrenia [poster]. APA's Institute on Psychiatric Services; October 29-November 2, 2003; Boston, MA